Drugs / CYAD-02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04167696 | Nov 2019 → Dec 2021 overdue | acute myeloid leukemia, myelodysplastic syndrome | Celyad Oncology SA | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYAD-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04167696 ↗ |
| Modality | Cell therapy | “CYAD-02 is a Chimeric Antigen Receptor-T (CAR-T) administered after CYFLU.” NCT04167696 ↗ |